Factors associated with acute cardiac injury and their effects on mortality in patients with COVID-19

Xingwei He1,5, Luyan Wang2,5, Hongjie Wang1, Yang Xie1, Yongfu Yu3, Jianhua Sun1, Jiangbo Yan4, Yuxin Du4, Yin Shen4*, & Hesong Zeng1*

To determine the incidence of acute cardiac injury (ACI), the factors associated with ACI and the in-hospital mortality in patients with COVID-19, especially in severe patients. All consecutive in-patients with laboratory-confirmed COVID-19 from Tongji Hospital in Wuhan during February 1 and March 29, 2020 were included. The demographic, clinical characteristics, laboratory, radiological and treatment data were collected. Univariate and Firth logistic regression analyses were used to identify factors associated with ACI and in-hospital mortality, and Kaplan–Meier method was used to estimate cumulative in-hospital mortality. Among 1031 patients included, 215 (20.7%) had ACI and 501 (48.6%) were severe cases. Overall, 165 patients died; all were from the severe group, and 131 (79.39%) had ACI. ACI (OR = 2.34, P = 0.009), male gender (OR = 2.58, P = 0.001), oximeter oxygen saturation (OR = 0.90, P < 0.001), lactate dehydrogenase (OR = 3.26, P < 0.001), interleukin-6 (IL-6) (OR = 8.59, P < 0.001), high sensitivity C-reactive protein (hs-CRP) (OR = 3.29, P = 0.016), N-terminal pro brain natriuretic peptide (NT-proBNP) (OR = 2.94, P = 0.001) were independent risk factors for the in-hospital mortality in severe patients. The mortality was significantly increased among severe patients with elevated hs-CRP, IL-6, hs-cTnI, and/or NT-proBNP. Moreover, the mortality was significantly higher in patients with elevation of both hs-cTnI and NT proBNP than in those with elevation of either of them. ACI develops in a substantial proportion of patients with COVID-19, and is associated with the disease severity and in-hospital mortality. A combination of hs-cTnI and NT-proBNP is valuable in predicting the mortality.

Abbreviations
- ACI: Acute cardiac injury
- COVID-19: Coronavirus disease 2019
- hs-CRP: High sensitivity C-reactive protein
- IL-6: Interleukin-6
- hs-cTnI: High-sensitivity cardiac troponin I
- NT-proBNP: N-terminal pro brain natriuretic peptide
- DM: Diabetes mellitus
- CHD: Coronary heart disease
- COPD: Chronic obstructive pulmonary disease
- CHF: Coronary heart failure

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in considerable morbidity and mortality worldwide since December 20191–4. Although acute respiratory failure due to diffuse alveolar damage is the leading cause of the death from COVID-19, lungs are not the only organs involved in the disease. A few studies have found that a substantial proportion of patients...
with confirmed COVID-19 suffer from acute cardiac injury (ACI), which may progress to heart failure, and thus increase the risk of in-hospital mortality in some cases. Furthermore, studies have shown that several inflammatory factors, such as high sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6), and cardiac injury indicators, such as high-sensitivity cardiac troponin I (hs-cTnI) and N-terminal pro brain natriuretic peptide (NT-proBNP), play important roles in the progression of COVID-19 and death. However, the sample sizes are relatively small in these studies, and the factors associated with ACI are still not well established. Moreover, it is unclear which factors or indicators (inflammatory or cardiac) have a greater value in predicting in-hospital mortality in COVID-19 patients.

Therefore, the aims of this large retrospective study were to determine the incidence of ACI, identify factors associated with ACI and evaluate the values of potential risk factors, such as inflammatory and cardiac injury indicators, in predicting in-hospital mortality in patients with laboratory-confirmed COVID-19, especially in severe cases.

Results
Demographics and clinical characteristics of patients. During February 1 and March 29, 2020, a total of 1348 suspected COVID-19 patients were hospitalized at Tongji Hospital, among which 154 patients were excluded—124 patients tested negative for nucleic acid, 6 patients with incomplete clinical data and 23 patients under the age of 18. Among the remaining 1195 eligible patients, 145 had no key data (hs-cTnI) in their medical records as of March 29, 2020. 17 patients had chronic renal failure and 2 patients suffered from acute myocardial infarction during hospitalization. Thus, 1031 patients were included in the final analysis (Figure S1). Of these patients, 530 and 501 were defined as mild and severe cases, respectively. As of March 29, 2020, 165 (16.0%) patients died during hospitalization and 866 (84.0%) recovered and were discharged from hospital. The median age was 63 years (range, 24–92 years; IQR, 52–70 years), and 538 (52.2%) were male. Hypertension (37.1%) was the most common comorbidity, followed by DM (18.3%) and CHD (8.1%). The most common symptoms on admission were fever (83.3%) and dry cough (69.4%), followed by dyspnea (25.7%) and diarrhea (17.2%) (Table 1). Compared with mild patients, severe patients were older, more male-predominant, and had more comorbidities (e.g. hypertension, DM, CHD, and COPD) and lower oxygen saturation (OOS, all \( P < 0.05 \)) (Table 1).

Severe patients had higher readings of the leukocyte count, alanine transaminase (ALT), IL-6, hs-CRP, hs-cTnI, and NT-proBNP and lower readings of the lymphocyte count and eGFR, compared with mild patients (all \( P < 0.05 \)) (Table 1). In terms of radiologic findings, bilateral pulmonary infiltration and ground-glass opacity or patchy shadows were more commonly present in severe patients than in mild patients (all \( P < 0.01 \) (Table 1).

Incidence of ACI and risk factors associated with ACI in all and severely patients. Overall, ACI, defined as hs-cTnI \( \geq \)99th percentile upper reference limit, occurred in 215 (20.9%) of the patients included in the study. The incidence was significantly higher in severe patients than in mild patients (37.7% vs. 4.9%, \( P < 0.001 \)). Compared with patients without ACI, patients who developed ACI were older, had more comorbidities (e.g. hypertension, DM, CHD, and COPD), lower readings of the lymphocyte count, eGFR and OOS, but higher readings of the leukocyte count, ALT, IL-6, hs-CRP, and NT-proBNP on admission (all \( P < 0.05 \)) (Table 2).

Specifically among severe patients, patients with ACI were also older (70 vs. 64 years, \( P < 0.001 \)), had lower OOS (90% vs. 93%, \( P < 0.001 \)), and more significant changes in inflammatory indicators (e.g. leukocyte count, lymphocyte count, hs-cTnI, and IL-6) than those without ACI (all \( P < 0.001 \)) (Table 2). In addition, patients with ACI had significantly lower eGFR than those without ACI (76.1 vs 91.2 mL/min/1.73 m\(^2\), \( P < 0.001 \)). The proportions of patients with concomitant hypertension, CHD and COPD were higher in patients with ACI than in those without ACI (52.4% vs. 44.2%, 14.3% vs. 9.0%, and 10.1% vs. 4.5%, and \( P = 0.080,0.077, \) and 0.024, respectively).

Risk of death of all patients and severe patients. A total of 165 (32.93%) patients, all with severe COVID-19, died at the hospital; ACI accounted for 79.39% (n = 131) of the death. The mortality rate was significantly higher in cases with ACI than in those without ACI (69.31% vs 10.86%, \( P < 0.001 \)) (Table 2). Logistic multiple regression analysis showed that ACI was an independent risk factor for the in-hospital mortality in severe patients (OR = 2.34, 95%CI 1.23–4.45; \( P = 0.009 \)). Other risk factors included: male gender (OR = 2.58; 95%CI 1.45–4.61; \( P = 0.001 \)), OOS (OR = 0.90, 95%CI 0.87–0.93, \( P < 0.001 \)), LDH (OR = 3.26, 95%CI 1.89–5.63; \( P < 0.001 \)), IL-6 (OR = 8.59, 95%CI 3.22–22.96; \( P < 0.001 \)), hs-CRP (OR = 3.29, 95%CI 1.25–8.66; \( P = 0.016 \)), and NT-proBNP (OR = 2.94, 95%CI 1.59–5.44; \( P = 0.001 \)) (Table 3).

All patients, as well as severe patients, were divided into “normal” and “elevated” groups according to the values of hs-CRP, IL-6, hs-cTnI and NT-proBNP. Kaplan–Meier method was used to estimate cumulative mortality proportion between the “normal” and “elevated” groups in terms of the four individual biomarkers, and between the “normal” and “elevated” groups of cardiac injury biomarkers in severe patients with elevated inflammatory biomarkers. The log-rank test showed that, in severe patients, the cumulative mortality proportion was significantly increased in the “elevated” group, for each of the four biomarkers (all \( P < 0.001 \) (Fig. 1A–D)). Similar results were also obtained when all patients were included in the analysis (all \( P < 0.001 \) (Figure S2)). Moreover, the elevation in the levels of hs-cTnI or/and NT-proBNP significantly increased the in-hospital mortality in severe patients with elevated inflammatory biomarkers (\( P < 0.001 \) (Fig. 1E); similar results were obtained for all patients (\( P < 0.001 \) (Figure S2).

Predictive value of serum hs-cTnI and NT-proBNP for cumulative in-hospital mortality among severe COVID-19 patients. When hs-cTnI and NT-proBNP were combined and used in Kaplan–Meier survival analysis, without consideration of the two inflammatory biomarkers, the mortality rates were the highest
| Demographics and clinical characteristics | Total (n = 1031) | Mild* (n = 530) | Severe* (n = 501) | P value |
|------------------------------------------|-----------------|-----------------|-------------------|---------|
| Age, median (IQR)-year                   | 63 (52–70)      | 60 (46–67)      | 66 (57–73)        | < 0.001 |
| Sex                                      |                 |                 |                   |         |
| Male                                     | 538 (52.2)      | 241 (45.5)      | 297 (59.3)        | < 0.001 |
| Female                                   | 493 (47.8)      | 289 (54.5)      | 204 (40.7)        | < 0.001 |
| Comorbidity                              |                 |                 |                   |         |
| Hypertension                             | 383 (37.1)      | 146 (27.5)      | 237 (47.3)        | < 0.001 |
| Diabetes mellitus                        | 189 (18.3)      | 66 (12.5)       | 123 (24.6)        | < 0.001 |
| CHD                                      | 83 (8.1)        | 28 (5.3)        | 55 (11.0)         | 0.001   |
| COPD                                     | 39 (3.8)        | 6 (1.1)         | 33 (6.6)          | < 0.001 |
| Malignancy                               | 29 (2.8)        | 11 (2.1)        | 18 (3.6)          | 0.187   |
| Cerebrovascular disease                  | 22 (2.1)        | 9 (1.7)         | 13 (2.6)          | 0.390   |
| Signs and symptoms                       |                 |                 |                   |         |
| Fever                                    | 859 (83.3)      | 430 (81.1)      | 429 (85.6)        | 0.055   |
| Dry cough                                | 716 (69.4)      | 363 (68.5)      | 353 (70.5)        | 0.500   |
| Dyspnea                                  | 265 (25.7)      | 71 (13.4)       | 194 (38.7)        | < 0.001 |
| Diarrhea                                 | 177 (17.2)      | 82 (15.5)       | 95 (19.0)         | 0.160   |
| Muscle ache                              | 137 (13.3)      | 74 (14.0)       | 63 (12.6)         | 0.522   |
| Chest tightness                          | 164 (15.9)      | 78 (17.8)       | 86 (17.2)         | 0.307   |
| Vital signs at presentation              |                 |                 |                   |         |
| Heart rate, bpm                          | 90 (80–102)     | 88 (80–100)     | 90 (80–104)       | 0.396   |
| Oximeter oxygen saturation, %            | 96 (92–97)      | 97 (96–98)      | 91 (85–93)        | < 0.001 |
| Systolic pressure, mmHg                  | 130 (120–144)   | 129 (119–140)   | 133 (120–145)     | 0.002   |
| Laboratory findings                      |                 |                 |                   |         |
| Leukocyte count (× 10^9/L)               | 5.8 (4.5–7.7)   | 5.3 (4.3–6.7)   | 6.6 (4.9–9.2)     | < 0.001 |
| <3.5 × 10^9/L                            | 89 (8.6)        | 53 (10.0)       | 36 (7.2)          | < 0.001 |
| ≥3.5 to <9.5 × 10^9/L                    | 802 (77.8)      | 455 (85.8)      | 347 (69.3)        |        |
| ≥9.5 × 10^9/L                            | 140 (13.6)      | 22 (4.2)        | 118 (23.6)        |        |
| Lymphocyte count (× 10^9/L)              | 1.1 (0.7–1.5)   | 1.3 (0.9–1.7)   | 0.8 (0.6–1.2)     | < 0.001 |
| <1.1 × 10^9/L                            | 539 (52.3)      | 189 (35.7)      | 350 (69.9)        | < 0.001 |
| Platelet count (× 10^9/L)                | 219.0 (164.0–288.0) | 229 (180–302) | 205 (149–272) | < 0.001 |
| <100 × 10^9/L                            | 46 (4.5)        | 2 (0.4)         | 44 (8.8)          | < 0.001 |
| Albumin (g/L)                            | 35.2 (31.7–39.3) | 37.6 (34.1–41.3) | 32.8 (29.9–36.1) | < 0.001 |
| <35 g/L                                  | 352 (34.1)      | 13 (33.3)       | 339 (67.7)        | < 0.001 |
| ALT (U/L)                                | 23.0 (15.0–39.0) | 21.0 (14.0–36.0) | 26.0 (17.0–40.2) | < 0.001 |
| ≥41 U/L                                  | 213 (20.7)      | 92 (17.4)       | 121 (24.2)        | 0.009   |
| eGFR (mL/min/1.73m²)                     | 91.8 (77.2–102.8) | 95.2 (83.6–105.3) | 87.3 (69.6–98.8) | < 0.001 |
| ≥90 mL/min/1.73m²                        | 563 (54.6)      | 339 (64.2)      | 224 (44.7)        | < 0.001 |
| ≥60 to <90 mL/min/1.73m²                 | 346 (33.6)      | 163 (30.9)      | 183 (36.5)        |        |
| ≥30 to <60 mL/min/1.73m²                 | 104 (10.1)      | 26 (4.9)        | 78 (15.6)         |        |
| <30 mL/min/1.73m²                        | 16 (1.6)        | 0 (0)           | 16 (3.2)          |        |
| LDH (U/L)                                | 266.0 (204.0–369.0) | 225.5 (186.3–281.8) | 334.5 (248.8–481.3) | < 0.001 |
| ≥250 U/L                                 | 564 (54.9)      | 190 (36.0)      | 374 (74.9)        | < 0.001 |
| IL-6 (pg/mL)                             | 6.7 (2.1–36.2)  | 3.4 (1.6–11.0)  | 21.2 (4.7–82.3)   | < 0.001 |
| ≥7 pg/mL                                 | 387 (37.5)      | 126 (24.0)      | 261 (52.1)        | < 0.001 |
| hs-CRP (mg/mL)                           | 22.3 (2.9–72.7) | 6.5 (2.1–31.1)  | 59.5 (16.2–111.2) | < 0.001 |
| ≥20 mg/L                                 | 517 (52.3)      | 155 (31.2)      | 362 (73.7)        | < 0.001 |
| D-dimer (µg/mL)                          | 0.7 (0.4–1.7)   | 0.5 (0.3–1.0)   | 1.3 (0.7–2.6)     | < 0.001 |
| ≥0.5 µg/mL                               | 657 (64.0)      | 235 (45.3)      | 422 (84.2)        | < 0.001 |
| hs-cTnI (pg/mL)                           | 5.3 (2.5–14.0)  | 3.3 (1.9–6.6)   | 9.7 (3.9–25.7)    | < 0.001 |
| ACI (≥99th percentile upper reference limit) | 215 (20.9)    | 26 (4.9)        | 189 (37.7)        | < 0.001 |
| NT-proBNP (pg/mL)                        | 124.0 (43.0–374.0) | 66.0 (27.0–155.0) | 281.0 (95.8–767.5) | < 0.001 |
| ≥486 pg/mL                               | 257 (24.8)      | 40 (8.2)        | 215 (42.9)        | < 0.001 |
| Imaging features                         |                 |                 |                   |         |
| Ground-glass opacity or patchy shadows   | 1009 (97.9)     | 511 (96.4)      | 498 (99.4)        | 0.007   |
| Bilateral pulmonary infiltration         | 959 (93.0)      | 468 (88.3)      | 491 (98.0)        | < 0.001 |
Table 1. Characteristics of enrolled patients and comparisons between mild and severe COVID-19 patients. Data are expressed as median (interquartile range) or number (%), where appropriate unless specifically indicated. *For analysis purpose, common and mild types were defined as “mild” and severe and critically ill types of COVID-19 were defined as “severe” type in the present study. ACI, acute cardiac injury; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; ALT, alanine transaminase.

| Variables                        | All patients (n = 1031) | Severe patients (n = 501)* |
|----------------------------------|-------------------------|--------------------------|
| Demographics                     |                         |                          |
| Age, median (IQR)-yr-yr          | 70 (62–77)              | 70 (62–77)               |
| Male                             | 119 (55.3)              | 112 (59.3)               |
| Major comorbidities              |                         |                          |
| Hypertension                     | 111 (51.6)              | 99 (52.4)                |
| Diabetes mellitus                | 55 (25.6)               | 50 (26.5)                |
| CHD                              | 32 (14.9)               | 27 (14.3)                |
| COPD                             | 20 (9.3)                | 19 (10.1)                |
| Vital signs at admission         |                         |                          |
| Heart rate (bpm)                 | 90 (80–104)             | 91 (80–106)              |
| Oximeter oxygen saturation, %    | 90 (80–93)              | 90 (83–93)               |
| Systolic pressure (mmHg)         | 135 (122–149)           | 136 (123–150)            |
| Laboratory findings              |                         |                          |
| Leukocyte count (x 10^9/L)       | 7.8 (5.4–11.5)          | 8.0 (5.9–12.4)           |
| Lymphocyte (x 10^9/L)            | 0.7 (0.5–1.0)           | 0.7 (0.5–0.9)            |
| ALT (U/L)                        | 28 (19–43)              | 28 (18–43)               |
| eGFR (ml/min/1.73m²)             | 77.1 (56.1–91.3)        | 76.1 (51.6–91.4)         |
| LDH (U/L)                        | 420.0 (275.0–588.5)     | 460.0 (307.0–613.0)      |
| hs-CRP (mg/L)                    | 72.5 (35.5–126.2)       | 78 (42.9–139.5)          |
| NT-proBNP (pg/mL)                | 761.0 (296.0–1548.8)    | 815 (302–1654)           |
| IL-6 (pg/L)                      | 59.4 (18.9–176.5)       | 49.6 (18.5–137.4)        |
| Treatments                       |                         |                          |
| Antibiotics                      | 201 (93.5)              | 179 (94.7)               |
| Antiviral treatment              | 176 (81.9)              | 151 (79.9)               |
| Corticosteroids                  | 156 (72.6)              | 146 (77.2)               |
| Intravenous immunoglobulin       | 110 (51.2)              | 102 (54.0)               |
| Non-invasive mechanical ventilation | 135 (62.8)            | 135 (71.4)               |
| Invasive mechanical ventilation  | 78 (36.3)               | 78 (41.3)                |
| Outcomes                         |                         |                          |
| Mortality                        | 131 (60.9)              | 131 (69.3)               |

Table 2. Comparisons between patients with acute cardiac injury (ACI) and those without ACI. Data are expressed as median (interquartile range) or number (%), where appropriate unless specifically indicated. *For analysis purpose, severe and critically ill types of COVID-19 were defined as “severe” type in the present study. ACI, acute cardiac injury; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; ALT, alanine transaminase; LDH, lactate dehydrogenase; IL-6, interleukin-6.

with elevated hs-cTnI and NT-proBNP, followed by elevated NT-proBNP and normal hs-cTnI, elevated hs-cTnI and normal NT-proBNP, and normal hs-cTnI and NT-proBNP (P < 0.001) (Fig. 2). Similar results were obtained for all enrolled patients (P < 0.001) (Figure S3).
Thus, based on our findings, we would propose that the definition of ACI should be not only similar to the inflammatory indicators, abnormalities in the cardiac injury indicators, hs-cTnI and NT-proBNP, thus is also used as an important cardiac function indicator. In the present study, death risk analysis showed that, our observations that ACI developed in over 20% of all cases and approximately 40% of severe cases with COVID-19, and was associated with almost 80% of the deaths suggest that ACI is a clinical condition that cannot be ignored in the course of COVID-19. Many factors may contribute to the development of ACI. In the present study, it was found that, compared with patients without ACI, patients with ACI showed notably abnormalities in many factors, including age, underlying comorbid diseases, blood oxygen saturation, inflammatory factors, kidney function, and cardiac injury indicators.

Multivariate analysis revealed that hs-CRP, IL-6, hs-cTnI, and NT-proBNP were important laboratory indicators which were independently associated with in-hospital death. HS-CRP and IL-6 are both vital inflammatory factors. While HS-CRP increases in patients with COVID-19, IL-6 promotes the secretion of antibodies by B lymphocytes and, specifically contributes to the function of natural killer lymphocytes. Recently, IL-6 has also been shown to be associated with the immune response to the inflammatory cascade storms in the advancement of COVID-19 in various recent studies. Thus the values of HS-CRP and IL-6 can prove to be exceptionally pivotal in predicting in-hospital mortality. However, it has not yet been investigated thoroughly.

hs-CRP has been suggested as a primary indicator for determining cardiac injury, which represents the degree of myocardial injury (ACI) and the occurrence of ACI has been confirmed to be associated with extremely high in-hospital mortality in COVID-19 patients, so the definition of ACI is critical to the prognosis of COVID-19 patients. NT-proBNP represents the change of intracardial pressure, especially atriolar pressure, and thus is also used as an important cardiac function indicator. In the present study, death risk analysis showed that, similar to the inflammatory indicators, abnormalities in the cardiac injury indicators, hs-cTnI and NT-proBNP, were associated with higher in-hospital mortality in all patients and in severe patients. The Kaplan–Meier curve charts demonstrated that among the patients with increased inflammatory indicators, the cumulative proportion of in-hospital mortality in patients with abnormal cardiac indicators was notably increased, which further confirmed that increased cardiac indicators had more important values than the inflammatory factors in the prognosis assessment of patients with COVID-19. Moreover, we found that the cumulative in-hospital mortality was significantly higher in patients with simultaneous increase of both hs-cTnI and NT-proBNP than inpatients with an increase of one of these indicator, suggesting that the combination of these two cardiac injury indicators would be more valuable than hs-cTnI alone in defining the presence of ACI and determining the prognosis of COVID-19 patients. Thus, based on our findings, we would propose that the definition of ACI should be not only

| Variable | Univariable OR (95% CI) | P value | Multivariable OR (95% CI) | P value |
|----------|-------------------------|---------|---------------------------|---------|
| Age, year | 1.06 (1.04–1.08) | <0.001 | 1.02 (1.00–1.04) | 0.107 |
| Male | 2.84 (1.97–4.09) | <0.001 | 2.58 (1.45–4.61) | 0.001 |
| Oximeter oxygen saturation, % | 0.81 (0.79–0.84) | <0.001 | 0.90 (0.87–0.93) | <0.001 |
| Leukocyte count, × 10⁹/L | | | | |
| ≥ 9.5 | 9.80 (6.60–14.57) | <0.001 | 1.73 (0.94–3.18) | 0.079 |
| ≤ 9.5 | 7.98 (4.97–12.80) | <0.001 | 1.76 (0.90–3.45) | 0.100 |
| LDH, U/L | | | | |
| ≥ 335 | 13.22 (8.82–19.83) | <0.001 | 3.26 (1.89–5.63) | <0.001 |
| ≤ 335 | 7.51 (4.97–11.97) | <0.001 | 1.64 (0.96–2.78) | 0.079 |
| IL-6, pg/mL | | | | |
| ≥ 7 | 25.51 (10.03–64.86) | <0.001 | 8.59 (3.22–22.96) | <0.001 |
| ≤ 7 | 7.98 (4.97–12.80) | <0.001 | 1.76 (0.90–3.45) | 0.100 |
| hs-CRP, mg/mL | | | | |
| ≥ 20 | 22.48 (10.06–50.22) | <0.001 | 3.29 (1.25–8.66) | 0.016 |
| ≤ 20 | 7.98 (4.97–12.80) | <0.001 | 1.76 (0.90–3.45) | 0.100 |
| NT-proBNP, pg/mL | | | | |
| ≥ 486 | 14.83 (10.01–21.99) | <0.001 | 2.94 (1.59–5.44) | 0.001 |
| ≤ 486 | 7.98 (4.97–12.80) | <0.001 | 1.76 (0.90–3.45) | 0.100 |
| hs-cTnI, pg/L | | | | |
| ≥ 99th percentile upper reference limit | 13.22 (8.94–19.55) | <0.001 | 2.34 (1.23–4.45) | 0.009 |
| ≤ 99th percentile upper reference limit | 7.98 (4.97–12.80) | <0.001 | 1.76 (0.90–3.45) | 0.100 |

Table 3. Univariate and multivariate regression analyses of risk factors associated with in-hospital mortality. LDH, lactate dehydrogenase; IL-6, interleukin-6.
Figure 1. Cumulative mortality rates among severe patients with COVID-19 according to the values of hs-cTnI, hs-CRP, NT-proBNP and IL-6. (A) Kaplan–Meier estimates representing the probability of death in the hospital according to the value of hs-cTnI; (B) Kaplan–Meier estimates representing the probability of death in the hospital according to the value of NT-proBNP; (C) Kaplan–Meier estimates representing the probability of death in the hospital according to the value of hs-CRP; (D) Kaplan–Meier estimates representing the probability of death in the hospital according to the value of IL-6. (E) Kaplan–Meier estimates representing the comparisons of probability of death in the hospital between two groups. A: elevated hs-cTnI or/and NT-proBNP and elevated hs-CRP or/and IL-6, B: normal hs-cTnI and NT-proBNP but elevated hs-CRP or/and IL-6.
based on hs-cTnI, but also on the cardiac function indicator, NT-proBNP. In other words, NT-proBNP should be added in the definition of ACI.

A few limitations existed in this study. First, not all laboratory studies, including IL-6 and NT-proBNP, were conducted on all patients because of the retrospective study nature. Their role in predicting in-hospital mortality may thus have been underestimated. Second, there was a shortage of data on arterial blood gas checks, electrocardiography and echocardiography in many cases due to unique circumstances during the epidemic, thereby restricting the estimation of the degree of ACI. Furthermore, this was a single-center study, and there may be selection bias. Therefore, to further validate the findings obtained in the present study, more prospective multi-centric clinical trials are required. In addition, in order to better understand the interaction between COVID-19 and ACI in the intact COVID-19 phase, thorough investigation is needed so as to optimize individual management of patients with COVID-19.

In conclusion, ACI develops in a substantial proportion of COVID-19 patients, and is associated with the disease severity and cumulative in-hospital mortality. The inflammatory factors, hs-CRP, and IL-6, and cardiac injury indicators, hs-cTnI and NT-proBNP, are all independent factors associated with the in-hospital mortality. Moreover, a combination of hs-cTnI and NT-proBNP is more valuable than the individual indicators alone in predicting the in-hospital mortality.

Methods

Patients and data collection. This study was conducted in accordance with the principles of the Declaration of Helsinki. The Institutional Review Board of Tongji Hospital, Wuhan, China, approved this retrospective study and written informed consent was waived (No. TJ-C20200140).

All consecutive inpatients who were hospitalized at Tongji Hospital (Wuhan China) with laboratory-confirmed COVID-19 during February 1 and March 29, 2020 were included in this retrospective study.

COVID-19 was diagnosed according to WHO interim guidance, namely, positive real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens for SARS-Cov-2 nucleic acid or positive serology for anti-SARS-Cov-2 specific IgM and/or IgG antibodies.

The medical data of patients electronically recorded in the hospital system were analyzed by a research team of the COVID-19, Tongji Hospital. For each patient, demographic and clinical data, including age, sex, physical examinations, clinical manifestations, concomitant diseases, laboratory findings, radiologic information, treatment and outcomes were obtained from the electronic medical records and collected in a case report form. The data of all eligible patients were then reviewed by a trained team of physicians.
Patients were excluded if they had the following conditions: (1), unavailability of key data, such as the inflammatory and cardiac injury factors described above; (2), a history of chronic renal insufficiency (i.e. chronic kidney disease ≥ stage 4), and acute myocardial infarction during hospitalization; and (3) patients less than 18 year-old. The date of disease onset was defined as the day when the symptoms of COVID-19 were noticed. Blood pressure, heart rate, and oxygen saturation were monitored regularly after admission. Initial laboratory investigations included complete blood count, liver and renal function tests, coagulation function, inflammatory biomarkers, such as hs-CRP and IL-6, and cardiac injury biomarkers, such as hs-cTnI and NT-proBNP. Chest X-ray radiograph or computed tomography (CT) scan were also performed for all inpatients, and the frequency of the examinations was determined by the treating physician. Concomitant diseases were identified as following: hypertension was diagnosed by clinical records of systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, or the use of antihypertensive agents before initial admission; diabetes mellitus (DM) was diagnosed by clinical records of fasting glucose levels ≥ 126 mg/dL, glycosylated hemoglobin A1c ≥ 6.5%, or treatment with oral hypoglycemic agents or insulin; and coronary heart disease (CHD) was defined as a previous history of myocardial infarction, or as coronary angiography showing stenosis ≥ 50% in any of the vessels, or as treatment with percutaneous coronary intervention or coronary artery bypass grafting.

Definition of ACI and categorization of severity of COVID-19. ACI was diagnosed if the serum level of hs-cTnI was above the 99th percentile upper reference limit, regardless of new abnormalities in electrocardiography and echocardiography[2,24]. The disease severity of COVID-19 was categorized as common, mild, severe, and critically ill according to the Chinese management guideline for COVID-19 (version 6.0) [25]. For analysis purpose, common and mild types were defined as “mild” and severe and critically ill types were defined as “severe” in the present study.

Statistical analysis. Descriptive data were expressed as mean ± standard deviation (SD) or median [range or interquartile range (IQR)] for continuous variables, where appropriate, and frequency and percentage for categorical factors. Comparison of continuous variables was evaluated by Student’s t test or Mann–Whitney U test as appropriate. Categorical variables were compared by the Fisher exact test or χ² test. Kaplan–Meier survival analysis was performed to estimate cumulative mortality rates and the log-rank test was used to determine the difference between groups. Firth logistic regression analysis was used to estimate odds ratio (OR) with 95% confidence interval (CI) to evaluate associations of demographic and clinical characteristics with COVID-19 in-hospital mortality. All analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC) or Stata 14 (StataCorp, College Station, TX, US).

Ethics declarations. This study was approved by the Ethics Committee of Tongji Hospital, Wuhan, China.

Data availability. The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.

Received: 24 July 2020; Accepted: 19 October 2020
Published online: 24 November 2020

References
1. Ji, Y., Ma, Z., Peppelenbosch, M. P. & Pan, Q. Potential association between COVID-19 mortality and health-care resource availability. Lancet Glob. Health 8, e480 (2020).
2. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395, 497–506 (2020).
3. Livingstone, E. & Bucher, K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA 323, 1335 (2020).
4. Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C. & Di Napoli, R. StatPearls (StatPearls Publishing, Treasure Island, 2020).
5. Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) 395, 1054–1062 (2020).
6. Shi, S. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 5, 802–810 (2020).
7. Chen, C. et al. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi 48, E008 (2020).
8. He, X. W., Lai, J. S., Cheng, J. & Zeng, H. Prognostic impact of cardiac injury in severe/critically severe patients with COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi 48, 456–460 (2020).
9. Zhang, C., Wu, Z., Li, J.-W., Zhao, H. & Wang, G.-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents 55, 105954 (2020).
10. Beagley, K. W. et al. Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J. Exp. Med. 169, 2133–2148 (1989).
11. López-Montalbés, M. et al. Antibody-dependent NK cell activation differentially targets EBV-infected cells in lytic cycle and bystander B lymphocytes bound to viral antigen-containing particles. J. Immunol. 190, 656–665 (2017).
12. Q. Ye, B. Wang, J. Mao, The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect, (2020).
13. Cao, X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 20, 269–270 (2020).
14. Qin, C. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. 71, 762–768 (2020).
15. Shah, A. S. V. et al. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet (London, England) 392, 919–928 (2018).
16. Willett, P. et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. J. Am. Coll. Cardiol. 70, 558–568 (2017).
17. Chen, T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368, m1091 (2020).
18. Li, B. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clin. Res. Cardiol.* **109**, 531–538 (2020).
19. Hu, Y. et al. Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. *J. Clin. Virol.* **127**, 104371 (2020).
20. Guo, T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA Cardiol.* **5**, 811–818 (2020).
21. Peng, Y. D. et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. *Zhonghua Xin Xue Guan Bing Za Zhi* **48**, E004 (2020).
22. Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y. & Xie, X. COVID-19 and the cardiovascular system. *Nat. Rev. Cardiol.* **17**, 259–260 (2020).
23. Guzik, T. J. et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. *Cardiovasc. Res.* **116**, 1666–1687 (2020).
24. Gao, C. et al. Association between cardiac injury and mortality in hospitalized patients infected with avian influenza A (H7N9) virus. *Crit. Care Med.* **48**, 451–458 (2020).
25. National Health Commission of the People’s Republic of China. Chinese management guideline for COVID-19 (version 6.0). [https://www.nhc.gov.cn/jkj/s3577/202003/4856db0458141fa9f376853224d41d7/files/4132b035bc242478a6ea1f57ce9d979.pdf](https://www.nhc.gov.cn/jkj/s3577/202003/4856db0458141fa9f376853224d41d7/files/4132b035bc242478a6ea1f57ce9d979.pdf) (2020).

**Acknowledgements**

The authors thank Medjaden Bioscience Limited for assisting in the preparation of the manuscript. We also thank Professor Ningling Sun from Medical Research Institute, Wuhan University Renmin Hospital, Wuhan University, Wuhan, China for support.

**Author contributions**

H.Z., Y.S. conceived the study and its design and take responsibility for the integrity of the data and accuracy of the analysis. X.H. and L.W. drafted the manuscript. H.W. and Y.X. were responsible for clinical data collection. Y.Y., J.S., J.Y., and Y.D. contributed to data analyses. All authors approved the final version of the article. The authors certify that: (1) the paper is not under consideration elsewhere, (2) no part of the paper has been previously published, (3) all of the authors have read and approved the manuscript. All authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

**Funding**

The project was supported by the Key Project of Health and Family Planning Commission of Hubei Province, China (No. WJ2017Z012) to HZ.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary information** is available for this paper at [https://doi.org/10.1038/s41598-020-77172-1](https://doi.org/10.1038/s41598-020-77172-1).

**Correspondence** and requests for materials should be addressed to Y.S. or H.Z.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. In these cases the licence is not included, you need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2020